Cancer treatment with c-met antagonists and correlation of the latter with HGF expression
US10240207B2 · kind B2 · utility
5Cited by
148References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 21, 2016 |
| Grant date | Mar 26, 2019 |
| Priority date | — |
| Expiry date | Sep 21, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/158
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention concerns cancer biomarkers. In particular, the invention concerns HGF as a biomarker for patient selection and patient prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.